DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+49.54%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$620M
AUM Growth
+$620M
(+21%)
Cap. Flow
+$120M
Cap. Flow
% of AUM
19.34%
Top 10 Holdings %
Top 10 Hldgs %
99.25%
Holding
17
New
5
Increased
3
Reduced
4
Closed
5
Top Buys
| 1 |
Intellia Therapeutics
NTLA
|
$301M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$32M |
| 3 |
Beam Therapeutics
BEAM
|
$16.3M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$6.21M |
| 5 |
ESSA Pharma
EPIX
|
$5.96M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$107M |
| 2 |
Fate Therapeutics
FATE
|
$89.8M |
| 3 |
Relay Therapeutics
RLAY
|
$24.3M |
| 4 |
Arvinas
ARVN
|
$9.29M |
| 5 |
MacroGenics
MGNX
|
$9.12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Intellia Therapeutics
NTLA
$1.22B
| $301M | 48.58% |
+1,859,926
| New | +$301M |
|
|
XLRN
2
DELISTED
Acceleron Pharma Inc.
XLRN
| $221M | 35.63% |
1,760,346
+255,334
| +17% | +$32M |
|
|
3
Fate Therapeutics
FATE
$120M
| $29.2M | 4.7% |
335,918
-1,034,215
| -75% | -$89.8M |
|
|
4
BridgeBio Pharma
BBIO
$9.89B
| $20.5M | 3.31% |
336,817
-1,753,332
| -84% | -$107M |
|
|
5
Beam Therapeutics
BEAM
$1.66B
| $16.3M | 2.64% |
+126,985
| New | +$16.3M |
|
|
VERV
6
DELISTED
Verve Therapeutics
VERV
| $6.21M | 1% |
+103,013
| New | +$6.21M |
|
|
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.21M | 1% |
225,480
+175,771
| +354% | +$4.84M |
|
|
8
ESSA Pharma
EPIX
$11.4M
| $5.96M | 0.96% |
+208,524
| New | +$5.96M |
|
9
Keros Therapeutics
KROS
$618M
| $4.43M | 0.71% |
104,186
+17,299
| +20% | +$735K |
|
10
Aclaris Therapeutics
ACRS
$209M
| $4.39M | 0.71% |
+250,000
| New | +$4.39M |
|
|
11
Relay Therapeutics
RLAY
$619M
| $4.38M | 0.71% |
119,775
-662,696
| -85% | -$24.3M |
|
12
Generation Bio
GBIO
$40.4M
| $289K | 0.05% |
10,738
-208,620
| -95% | -$5.61M |
|
|
13
Arvinas
ARVN
$568M
| – | – |
-140,511
| Closed | -$9.29M |
|
14
C4 Therapeutics
CCCC
$185M
| – | – |
-140,034
| Closed | -$5.18M |
|
15
Fulcrum Therapeutics
FULC
$351M
| – | – |
-49,868
| Closed | -$587K |
|
16
Immunovant
IMVT
$2.56B
| – | – |
-65,849
| Closed | -$1.06M |
|
|
17
MacroGenics
MGNX
$112M
| – | – |
-286,195
| Closed | -$9.12M |
|